An observational study of alemtuzumab following fingolimod for multiple sclerosis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received October 5, 2016
- Accepted in final form December 5, 2016
- First Published January 10, 2017.
Author Disclosures
- Mark Willis, BSc, MBBCh, MRCP,
- Owen Pearson, MBBCh, MD, FRCP,
- Zsolt Illes, MD, PhD,
- Tobias Sejbaek, MD,
- Christian Nielsen, MSc, PhD,
- Martin Duddy, MD, FRCP,
- Kate Petheram, BSc, MBChB, MRCP,
- Caspar van Munster, MD, PhD,
- Joep Killestein, MD, PhD,
- Clas Malmeström, MD, PhD,
- Emma Tallantyre, PhD, MRCP and
- Neil Robertson, MD, FRCP
- Mark Willis, BSc, MBBCh, MRCP,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Wellcome Trust Research Training Fellowship
NONE
NONE
NONE
NONE
NONE
NONE
- Owen Pearson, MBBCh, MD, FRCP,
(1)Biogen, Novartis, Roche (2)UK MS register
NONE
(1) Biogen, Roche, Merck Serono, Novartis, Teva, Genzyme Sanofi.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Zsolt Illes, MD, PhD,
(1) Biogen Idec (2) Novartis (3) Sanofi-Aventis-Genzyme (4) Teva Pharmaceuticals
NONE
(1) Biogen Idec (2) Novartis (3) Sanofi-Aventis-Genzyme (4) Teva Pharmaceuticals (5) Bayer Healthcare (5) Merck Serono
Clinical and Experimental Neuroimmunology
Lambertsen K, Clausen B, Nielsen HH, Finsen B, Illes Z. 2015. Fumaric acid derivates for Medical use. No. PCT/DK2015/050344. The use of fumaric acid derivates in acute ischemic stroke.
NONE
NONE
NONE
NONE
NONE
NONE
(1) Biogen Idec
(1)Region of Southern Denmark, primary investigator, 2014
(1)Odense University Hospital
(1)Scleroseforeningen (2) Lundbeckfonden (3) Direktor Ejnar Jonasson, kaldet Johnsen, og Hustru's Mindelegat
NONE
NONE
NONE
NONE
NONE
NONE
- Tobias Sejbaek, MD,
Novartis, Biogen, Teva, Merck, Roche
NONE
Biogen, Teva, Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christian Nielsen, MSc, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Martin Duddy, MD, FRCP,
NONE
NONE
(1) Sanofi Genzyme, speaker honoraria, travel to conference, advisory board (2) Novartis, speaker honoraria, travel to conference, advisory board (3) Biogen, speaker honoraria, travel to conference, advisory board (4) Merck, speaker honoraria (5) Teva, speaker honoraria, travel to conference (6) Roche, honorarium for development of educational programme, advisory board (7) Medscape, development and delivery of online educational programme
Multiple Sclerosis Journal, Associate Editor, 2013-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Novartis (2) Biogen (3) Roche (4) Sanofi Genzyme
NONE
NONE
(1) MS Trust, London, UK
NONE
NONE
NONE
NONE
NONE
NONE
- Kate Petheram, BSc, MBChB, MRCP,
(1) Roche Product Limited. Scientific advisory board.
NONE
(1) Genzyme Sanofi. Funding for travel and speaker honoraria. (2) Biogen Idec. Funding for travel.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Caspar van Munster, MD, PhD,
(1) Commercial, compensation for serving in a scientific advisory board from Merck Serono.
NONE
(1) Commercial, honoraria for lecturing and consulting from Novartis Pharma AG (2) Commercial, honoraria for lecturing and consulting from Biogen-Idec (3) Commercial, honoraria for lecturing and consulting from Merck Serono
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Joep Killestein, MD, PhD,
Consultancy (advisory boards) Novartis, Merck-Serono, Biogen, Genzyme, TEVA, Roche
NONE
Speaker honoraria Biogen, Novartis, TEVA, Merck-Serono, Roche
Editor of the official scientific journal of the Dutch Society of Neurology, the Dutch Society of Neurosurgeons and the Society of Flemish Neurologists (Tijdschrift voor Neurologie en Neurochirurgie). Editorial board MS Journal
NONE
NONE
NONE
Consultancy Novartis, Merck-Serono, Biogen Idec, Genzyme, TEVA
NONE
NONE
NONE
I have been involved in clinical trials of companies that market drugs for MS (Schering AG, Biogen Idec, Merck-Serono, Teva, Genzyme, Novartis and Roche).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Clas Malmeström, MD, PhD,
(1)Biogen-Idec, Merck-Serono, Novartis and Roche
NONE
(1) Biogen-Idec, Merck-Serono, Novartis and Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Emma Tallantyre, PhD, MRCP and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I received salary from Biogen Idec as part of a fellowship scheme.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Neil Robertson, MD, FRCP
Professor Robertson has served on Advisory boards for Genzyme, Roche, Novartis, Biogen
NONE
Professor Robertson has recieved honoraria for speaking at academic meetings from Biogen and Genzyme
Professor robertson serves as an editor for the Journal of Neurology since 2012
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Neuroimmunology Fellowship Genzyme Mortality of MS Novartis
National institute of Heath Wales, co-applicant 2015-18
NONE
Multiple Sclerosis society of Great Britain and Northern Ireland Welcome Trust
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (M.W., E.T., N.R.), Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, University Hospital of Wales; Department of Neurology (O.P.), Morriston Hospital, Heol Maes Eglwys, Morriston, Swansea, UK; Departments of Neurology (Z.I., T.S.) and Clinical Immunology (C.N.), Odense University Hospital, University of Southern Denmark; Department of Neurology (M.D.), The Royal Victoria Infirmary, Newcastle upon Tyne; Department of Neurology (K.P.), Sunderland Royal Hospital, UK; VU University Medical Center (C.v.M., J.K.), Amsterdam, the Netherlands; and Department of Neurology (C.M.), Sahlgrenska Academy at the University of Gothenburg, Institute of Clinical Neuroscience and Physiology, Gothenburg, Sweden.
- Correspondence to Dr. Robertson: RobertsonNP{at}cardiff.ac.uk
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Articles
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical TrialA.J. Coles, E. Fox, A. Vladic et al.Neurology, March 21, 2012 -
Views & Reviews
AlemtuzumabThe advantages and challenges of a novel therapy in MSTil Menge, Olaf Stüve, Bernd C. Kieseier et al.Neurology, June 11, 2014 -
Article
Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumabHeinz Wiendl, Matthew Carraro, Giancarlo Comi et al.Neurology: Neuroimmunology & Neuroinflammation, October 29, 2019 -
Article
Alemtuzumab CARE-MS II 5-year follow-upEfficacy and safety findingsAlasdair J. Coles, Jeffrey A. Cohen, Edward J. Fox et al.Neurology, August 23, 2017